Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC

Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC

Presented By
Prof. Caicun Zhou, Shanghai Pulmonary Hospital, China
Conference
ELCC 2022
Trial
Phase 2
Doi
https://doi.org/10.55788/5c16332a
Results from a single-arm, phase 2 trial demonstrated a potential clinical benefit of the third-generation EGFR tyrosine kinase inhibitor oritinib in patients with EGFR T790M-mutated non-small cell lung cancer (NSCLC) who had prior treatment with EGFR tyrosine kinase inhibitors. First-line treatment with an EGFR tyrosine kinase inhibitor is standard of care in patients with locally advanced/metastatic EGFR-mutated NSCLC. However, in most patients treated with first-generation EGFR tyrosine kinase inhibitors, progression of disease eventually occurs due to the development of an EGFR T790M mutation. Second-line treatment with a selective third-generation EGFR tyrosine kinase inhibitor, like osimertinib, has been shown to improve survival over chemotherapy in EGFR T790M-mutated NSCLC patients [1]. Oritinib is a newly developed third-generation EGFR tyrosine kinase inhibitor that was recently tested in a phase 2 trial (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on